DelveInsight Business Research LLP

DelveInsight’s “Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2032“  report delivers an in-depth understanding of the Post-Transplant Lymphoproliferative Disorder, historical and forecasted epidemiology as well as the Post-Transplant Lymphoproliferative Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Post-Transplant Lymphoproliferative Disorder market report provides current treatment practices, emerging drugs, Post-Transplant Lymphoproliferative Disorder market share of the individual therapies, current and forecasted Post-Transplant Lymphoproliferative Disorder market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Post-Transplant Lymphoproliferative Disorder treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Post-Transplant Lymphoproliferative Disorder market.

Some of the Key Facts of the Parainfluenza Virus Infection Market Report:

• As per Delveinsight estimates, the total prevalence rate of PIV infections in Hematopoietic Stem Cell Transplant (HSCT) patients in the US is estimated to be 7% in the year 2021.

• Based on secondary research, it was found that HPIVs primarily affect young children, in whom the pathogenic spectrum includes upper and lower respiratory tract infections. They are responsible for 30%-40% of all acute respiratory tract infections in infants and children   

 Key Benefits of the Parainfluenza Virus Infection Market Report:

• The report covers the descriptive overview of Post-Transplant Lymphoproliferative Disorder, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Post-Transplant Lymphoproliferative Disorder epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Post-Transplant Lymphoproliferative Disorder is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of the Post-Transplant Lymphoproliferative Disorder market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Post-Transplant Lymphoproliferative Disorder market

Got queries? Click here to know more about the Parainfluenza Virus Infection Market Landscape

Parainfluenza Virus Infection Overview

Parainfluenza refers to a group of viruses called human parainfluenza viruses (HPIVs). The human parainfluenza virus (HPIV) is an enveloped, negative-sense, single-stranded RNA virus that belongs to the family of Paramyxoviridae. It is classified into four serotypes numbered 1 to 4 (HPIV-1, HPIV-2, HPIV-3, and HPIV-4). Serotype 4 can even be subdivided into HPIV-4A and HPIV-4B. Human parainfluenza viruses (HPIVs) commonly cause upper and lower respiratory illnesses in infants, young children, older adults, and people with weakened immune systems, but anyone can get infected. After you get infected, it takes about 2 to 7 days before you develop symptoms. It is one of the major causes of morbidity and mortality in infants worldwide. These respiratory viruses were first observed in the late 1950s when they were isolated from children with croup and were known as croup-associated viruses.

The pathogenesis of the parainfluenza virus consists of the host’s immune response and viral mechanisms. The attachment and the fusion of the virus to the host cell are mediated by the virus surface proteins hemagglutinin-neuraminidase (HN) and fusion glycoproteins (F) with the sialic acid residues on the surface of host epithelial cells respectively.[1] Transcription and maturation are mediated by the actin and the cytoskeleton, which also play a role in the movement of viral glycoproteins toward the surface of the host cells.

Parainfluenza Virus Infection Epidemiological Insights:

• The total diagnosed prevalent population of PIV Infection in the 7 major markets was 1,900,310 in 2021. In the case of PIV Infection patients in the United States, the diagnosed prevalent population was found to be 766,630 in 2021, which is anticipated to increase during the forecasted period.

• In the EU5 countries, the diagnosed prevalent population of PIV Infection was maximum in Germany with  101,105 followed by the United Kingdom with 75,235 in 2021. While, the least number of cases were found in Italy, in 2021.

• In Japan, the diagnosed prevalent population of PIV Infection was found to be  65,378 in 2021.

• As per the study conducted by L. Min et al. titled “Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children”, wherein analysis was done on PIV hospitalized cases, the age-specific incidence rates of PIV3 hospitalization ranged from approximately 0.13 per 100 to 0.68 per 100 for infants

Parainfluenza Virus Infection Epidemiological Segmentation 

• Parainfluenza Virus Infection prevelant cases 

• Parainfluenza Virus Infection incident cases 

• Parainfluenza Virus Infection diagnosed cases 

• Parainfluenza Virus Infection treatment cases 

Parainfluenza Virus Infection Market Outlook 

The Post-Transplant Lymphoproliferative Disorder market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Post-Transplant Lymphoproliferative Disorder market trends by analyzing the impact of current Post-Transplant Lymphoproliferative Disorder therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Post-Transplant Lymphoproliferative Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Post-Transplant Lymphoproliferative Disorder market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Post-Transplant Lymphoproliferative Disorder market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Parainfluenza Virus Infection Market  Landscape

Parainfluenza Virus Infection Key Companies

• Ansun Biopharma 

• Alovir Pharma

• And many others 

Parainfluenza Virus Infection Key Therapies 

• DAS 181 

• ALVR 106

• And many others 

Table of Contents

1.  Key Insights 

2.  Parainfluenza Virus Infection Report Introduction 

3.  Executive Summary of the Parainfluenza Virus Infection Market  

4.  Parainfluenza Virus Infection Disease Background and Overview

5.  Parainfluenza Virus Infection Epidemiology and patient population

6.  The United States 

7.  EU4

8.  Parainfluenza Virus Infection Market Emerging Therapies

9.  Parainfluenza Virus Infection Market Drivers 

10.  Parainfluenza Virus Infection Market Barriers 

11.  Market Access and Reimbursement of Therapies

12.  Appendix

13.  Parainfluenza Virus Infection Market Report Methodology

14.  DelveInsight Capabilities

15.  Disclaimer

16.  About DelveInsight

Click here to read more about Parainfluenza Virus Infection Market Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/